Genomics

NVIDIA CEO Jensen Huang wins the 2026 IEEE Medal of Honor, a nod to his visionary work that sparked an AI revolution and a $5 trillion empire.

PacBio heads to J.P. Morgan's conference with new tech aimed at making long-read sequencing cheaper. Can it challenge rivals and win over investors?

As CooperCompanies heads to the J.P. Morgan conference, all eyes are on CEO Al White's strategic vision for its dual vision and women's health units.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A unique partnership brings accessible genetic testing to Boca Raton, using a community race to empower families with critical health knowledge.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

At JSHG 2025, Nabsys presents its OhmX platform, a breakthrough in electronic genome mapping that promises to solve rare disease mysteries and advance cancer research.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

A major hedge fund's move in a $2.4B semiconductor deal reveals a critical truth: the future of precision medicine is built on high-speed data infrastructure.

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?

A new alliance between Guardant Health and Trial Library uses AI and massive datasets to dismantle barriers, connecting more patients to vital cancer research.

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.